Roche Holding AG / SAGA Diagnostics AB

Oncology molecular residual disease (MRD) monitoring across solid tumors

2M US cases/yr · $1.7B Global MRD testing market (2023) · $6,670 Global MRD testing market 2033 forecast (USD millions, 14.8% CAGR)

Disease Overview

Molecular residual disease (MRD) detection uses ultra-sensitive sequencing of circulating tumor DNA (ctDNA) to identify cancer recurrence months to years before imaging or clinical symptoms. MRD testing is emerging as a pivotal oncology workflow across the cancer journey: adjuvant therapy decisions (post-surgical stratification of recurrence risk), neoadjuvant response assessment, immunotherapy response monitoring, and surveillance. The addressable population spans the ~2 million US cancer diagnoses annually (ACS 2026 estimate) and ~18 million US cancer survivors under surveillance. Tumor-informed assays (custom-built from each patient's tumor WGS/WES) offer higher sensitivity than tumor-agnostic assays and have become the clinical gold standard. Medicare coverage through MolDx has accelerated reimbursement, with Natera's Signatera currently covered for colorectal, muscle-invasive bladder, breast, and ovarian cancers. The MRD testing market was valued at $1.67B in 2023 and is forecast to reach $6.67B by 2033 (14.8% CAGR). Natera holds 90-95% market share via Signatera. SAGA Diagnostics' Pathlight uses whole-genome sequencing and digital PCR to identify patient-specific structural variants and has Medicare coverage for early-stage breast cancer. This deal integrates Pathlight into Foundation Medicine's tumor-profiling franchise. Primary source: Grand View Research Minimal Residual Disease Testing Market Report 2030.

Competitive Landscape

The MRD/ctDNA diagnostics landscape is concentrated around tumor-informed vs tumor-agnostic approaches. (1) Tumor-informed leaders — Natera's Signatera (personalized 16-plex PCR panel from tumor WES) dominates with ~90-95% market share and broad Medicare coverage; Natera acquired Foresight Diagnostics (phased variant technology) in Dec 2025, and submitted PMA for Signatera as a CDx in Feb 2026. SAGA's Pathlight uses whole-genome sequencing + digital PCR for structural variants, a technically differentiated approach now absorbed into Foundation Medicine. (2) Tumor-agnostic / fixed-panel — Guardant Health's Guardant Reveal is the first tissue-free tumor-agnostic ctDNA MRD test, with strong colorectal and solid-tumor positioning; Guardant acquired MetaSight Diagnostics for $149M in 2025. (3) Other entrants — Exact Sciences' Oncodetect, Invitae (now Labcorp) PCM, Personalis's NeXT Personal, Myriad Genetics Precise MRD. (4) Pharma-integrated MRD — Roche/Foundation Medicine's AXELIOS sequencing + Digital LightCycler PCR platforms combined with Pathlight creates a vertically integrated MRD franchise paired with tumor profiling, positioning Roche against Natera's Signatera and Guardant Reveal.